Intranasal benzodiazepine pharmaceutical compositions
OwnerGary Bream, Moise A. Khayrallah +3inventors
InventorsGary Bream, Moise A. Khayrallah, Myoung-Ki Baek, Jae-Hoon Jo, Hye-Jin Chang
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.
Claims39
A pharmaceutical composition comprising about 1% to about 15% by weight of a benzodiazepine or a pharmaceutically acceptable salt thereof, about 43% to about 55% by weight of a glycol ether, about 16% to about 18% by weight one or more fatty acid esters, about 22% to about 25% by weight N-methyl-2-pyrrolidone, about 1% to about 5% by weight water, and about 5% to about 10% by weight ethanol.
A pharmaceutical composition comprising about 1% to about 10% by weight of a benzodiazepine or a pharmaceutically acceptable salt thereof, about 40% to about 47% by weight of a glycol ether, and about 45% to about 55% by weight one or more fatty acid esters.
A pharmaceutical composition for intranasal administration of diazepam, comprising diazepam or a pharmaceutically acceptable salt thereof, a glycol ether, and one or more fatty acid esters, wherein upon administration to a human subject, plasma levels of diazepam exhibit a coefficient of variation (CV) of less than about 40%.
Dependencies are inferred from the claim text.